Rapid antibiotic-resistance tests

01Overview and value chain#

Markers EC: IVDR 2017/746 | OECD: Biotech-health | Regulator: FDA (USA), EMA (European Union), NMPA (China)

Rapid antibiotic-resistance tests determine which antibiotics a specific infecting pathogen is susceptible or resistant to in hours rather than the 2-3 days conventional culture-based antibiotic susceptibility testing (AST) requires, letting clinicians switch from broad-spectrum empiric therapy to a targeted antibiotic sooner — a direct lever against antimicrobial resistance and unnecessary broad-spectrum antibiotic use. Accelerate Diagnostics’ Accelerate Pheno system runs rapid phenotypic AST directly from a positive blood culture, with its clinical performance documented across multiple peer-reviewed studies. T2 Biosystems’ T2Resistance Panel uses magnetic-resonance-based detection to identify antibiotic-resistance genes directly from a blood sample without waiting for culture, with the company continuing to publish clinical-benefit data and advance its product pipeline. Q-linea’s ASTar system runs rapid phenotypic AST directly from positive blood culture, and the company recently announced FDA clearance of an expanded ASTar blood-testing menu. Selux Diagnostics has patented a parallel-processing antimicrobial susceptibility testing system and method, aiming to run many antibiotic-pathogen combinations simultaneously. In China, Autobio Diagnostics (安图生物), a major domestic in-vitro diagnostics company, participates in the country’s antibiotic-susceptibility and broader IVD testing market.

The key directions of rapid antibiotic-resistance tests are:

1. Rapid phenotypic AST from blood culture (Rapid Phenotypic AST): growth-based susceptibility testing run directly from a positive blood culture, returning a full susceptibility profile in hours instead of days — Accelerate Diagnostics’ Accelerate Pheno, Q-linea’s ASTar.
2. Molecular resistance-gene detection (Molecular Resistance Detection): direct-from-blood detection of specific antibiotic-resistance genes without waiting for a positive culture — T2 Biosystems’ T2Resistance Panel.
3. Parallel-processing AST platforms (Parallel Processing AST): engineering approaches that test many antibiotic-pathogen combinations simultaneously to compress overall turnaround time — Selux Diagnostics.
4. Domestic AST/IVD platforms (Domestic AST Platforms): regionally manufactured antibiotic-susceptibility and broader in-vitro diagnostic platforms serving a domestic clinical-microbiology market — Autobio Diagnostics.

Sectoral value chain#

[positive blood culture / isolate sample] ──> [rapid AST or molecular resistance-gene analysis] ──> [susceptibility profile / resistance-gene result]
                                                    │
                                       (regulatory clearance: FDA/IVDR/NMPA)
                                                    │
                                                    ▼
[antimicrobial stewardship & outcome tracking] <─── [clinical antibiotic selection decision] <─────┘

Value chain levels#

Cross-cutting technologies of the sector:

• Rapid phenotypic susceptibility testing (Rapid Phenotypic AST): growth-based methods measure whether the pathogen actually grows in the presence of each antibiotic, compressed from days to hours through automated imaging and analysis, as in Accelerate Pheno and Q-linea’s ASTar.
• Magnetic-resonance molecular detection (Molecular Resistance Detection): T2 Biosystems’ magnetic-resonance technology detects resistance genes and pathogen signatures directly from whole blood, bypassing the culture step entirely.
• Parallel antibiotic-pathogen processing (Parallel Processing AST): engineering multiple simultaneous antibiotic-exposure conditions, per Selux Diagnostics’ patented approach, compresses the number of sequential test cycles needed to cover a full antibiotic panel.

02US#

The US anchors the deepest bench of rapid AST and molecular resistance-detection companies, spanning phenotypic, molecular and parallel-processing approaches.

Accelerate Pheno, T2Resistance, Selux, FDA#

• Accelerate Diagnostics: its Accelerate Pheno system runs rapid phenotypic antibiotic susceptibility testing directly from a positive blood culture, with clinical performance documented across multiple peer-reviewed studies.
• T2 Biosystems: its T2Resistance Panel uses magnetic-resonance-based detection to identify antibiotic-resistance genes directly from blood without waiting for culture, continuing to publish clinical-benefit data and advance its product pipeline.
• Selux Diagnostics: has patented a parallel-processing antimicrobial susceptibility testing system and method, aiming to test many antibiotic-pathogen combinations simultaneously to compress turnaround time.
• FDA framework: rapid AST platforms clear the FDA via 510(k)/PMA review as in-vitro diagnostic devices, with each expanded antibiotic or pathogen menu typically requiring its own regulatory clearance.

03CN#

China hosts a growing domestic in-vitro diagnostics base for antibiotic susceptibility and broader clinical microbiology testing, with Autobio Diagnostics among the major domestic providers.

Autobio Diagnostics, NMPA#

• Autobio Diagnostics (安图生物): a major domestic in-vitro diagnostics company, participates in China’s antibiotic-susceptibility and broader IVD testing market.
• NMPA framework: antibiotic-susceptibility testing platforms and reagents in China require NMPA approval as in-vitro diagnostic products, with domestic manufacturers competing alongside imported rapid-AST platforms.

04EU#

Sweden anchors Europe’s rapid AST capacity through Q-linea, which recently secured FDA clearance for an expanded version of its rapid phenotypic testing platform.

Q-linea, ASTar, IVDR#

• Q-linea: its ASTar system runs rapid phenotypic antibiotic susceptibility testing directly from positive blood culture, and the company recently announced FDA clearance of an expanded ASTar blood-testing menu, extending the platform’s antibiotic and pathogen coverage.
• IVDR framework: rapid AST platforms sold in the EU require conformity assessment and CE marking under the In Vitro Diagnostic Regulation (IVDR 2017/746), with Q-linea’s home Swedish market operating under this framework alongside its separate FDA clearance for the US.

05Leading companies and research institutes#

06Tech stack and innovations#

The stack spans three distinct technical routes to the same goal — a susceptibility or resistance result in hours rather than days — phenotypic growth-based testing, molecular resistance-gene detection, and engineered parallel processing.

1. Rapid phenotypic AST (Rapid Phenotypic AST):
   • Accelerate Diagnostics’ Accelerate Pheno and Q-linea’s ASTar both run automated, imaging-based growth assessment directly from a positive blood culture, compressing conventional 2-3-day susceptibility testing into hours.
2. Molecular resistance-gene detection (Molecular Resistance Detection):
   • T2 Biosystems’ T2Resistance Panel applies magnetic-resonance technology to detect resistance genes directly from whole blood, bypassing the culture-growth step that phenotypic methods still require.
3. Parallel antibiotic-pathogen processing (Parallel Processing AST):
   • Selux Diagnostics’ patented system and method run many antibiotic-pathogen exposure conditions simultaneously, engineering around the sequential-testing bottleneck that limits how fast a full antibiotic panel can be completed.
4. Domestic AST manufacturing (Domestic AST Platforms):
   • Autobio Diagnostics manufactures antibiotic-susceptibility and broader in-vitro diagnostic platforms for China’s domestic clinical-microbiology market.

07Value chains and production pipelines#

Industrial pipeline of a rapid antibiotic-resistance test (FDA 510(k)/PMA / EU IVDR 2017/746)#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Sample input           │ ───> │ 2. Rapid AST / molecular  │
│    (positive culture)      │      │    analysis                 │
└───────────────────────────┘      └───────────────────────────┘
                                                   │
                                                   ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Regulatory clearance   │ <─── │ 3. Result generation      │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Clinical antibiotic    │ ───> │ 6. Antimicrobial          │
│    selection                │      │    stewardship               │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Sample input

A positive blood culture (Accelerate Pheno, ASTar, T2Resistance) or clinical isolate identifying the infecting pathogen enters the rapid-testing workflow.

Stage 2: Rapid AST or molecular analysis

The platform runs phenotypic growth-based susceptibility testing across a panel of antibiotics, or molecular detection of specific resistance genes, depending on whether it follows the phenotypic (Accelerate Diagnostics, Q-linea) or molecular (T2 Biosystems) approach.

Stage 3: Result generation

The platform reports a susceptibility profile (susceptible/intermediate/resistant per antibiotic tested) or a resistance-gene detection call, typically within hours of sample input.

Stage 4: Regulatory clearance

The AST platform and each antibiotic or pathogen menu clears FDA 510(k)/PMA review, EU IVDR conformity assessment, or NMPA registration, with expanded menus (such as Q-linea’s 2026 ASTar expansion) requiring their own clearance.

Stage 5: Clinical antibiotic selection

The treating physician uses the rapid result to switch from broad-spectrum empiric therapy to a targeted antibiotic hours or days sooner than conventional culture-based AST would allow.

Stage 6: Antimicrobial stewardship

Hospital antimicrobial-stewardship programs track prescribing patterns and resistance trends enabled by faster, more targeted antibiotic selection, closing the loop between rapid diagnostics and reduced unnecessary broad-spectrum antibiotic use.